PROCEPT BioRobotics (NASDAQ:PRCT) recently exceeded revenue expectations, with a loss smaller than anticipated. Analysts predict a 23% revenue increase in 2024, with a slight improvement in loss per share.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing